Ms Priyankaa Goordyal

Centre for Cancer and Inflammation

Exploring the novel combinations of immunotherapies for the treatment of lung cancer.
Our preliminary results have shown a 30-40% reduction in tumour volume in KRAS driven lung tumours when treated with Acalabrutinib. In this study, we aim to explore the therapeutic effect of Acalabrutinib when combined with STAT3 inhibition in the hope to achieve a better treatment response

This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.